EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis

M Tarrants, M Oleen-Burkey, J Castelli-Haley, M J Lage

Multiple Sclerosis International · 2011

DOI: 10.1155/2011/271321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis International, 2011. Verfasst von M Tarrants und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Teva Pharmaceuticals, 901 East 104th Street, Suite 900, Kansas City, MO 64131, USA. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Examine the impact of comorbid depression on adherence to disease-modifying therapy (DMT) for multiple sclerosis (MS).

Methods

A retrospective database was used to identify patients with MS treated with a DMT. Patients with MS and comorbid depression were matched to patients with MS only. Adherence to DMT was proxied by the medication possession ratio (MPR) and multivariate regressions were used to examine the association between comorbid depression and adherence to DMT.

Results

Patients with comorbid depression had a 10 point lower MPR ( P < 0.01 ) and were less likely to achieve a MPR of at least 80% (odds ratio (OR) = 0.55 ; 95% confidence interval (CI) 0.42–0.74) than those without depression. While treatment with an antidepressant generally had no significant impact on the likelihood of achieving an MPR threshold of 80% ( OR = 1.32 ; 95% CI 0.50–3.48), adherence to antidepressant therapy guidelines were associated with improved adherence to DMT therapy.

Conclusions

MS patients with comorbid depression were approximately half as likely to be adherent to their DMT relative to patients with MS without depression. Although treatment with antidepressant therapy generally did not improve the likelihood of adherence, treatment with antidepressants for at least 6 months was associated with better adherence to DMT.

Autor:innen und Institutionen

  • Medical Affairs, Teva Pharmaceuticals, 901 East 104th Street, Suite 900, Kansas City, MO 64131, USA.

Zitieren

APA

Tarrants, M., Oleen-Burkey, M., Castelli-Haley, J., & Lage, M. J. (2011). The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis. Multiple Sclerosis International. https://doi.org/10.1155/2011/271321

Vancouver

Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis. Multiple Sclerosis International. 2011. doi:10.1155/2011/271321

BibTeX
@article{Tarrants2011,
  author = {Tarrants, M and Oleen-Burkey, M and Castelli-Haley, J and Lage, M J},
  title = {The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis},
  journal = {Multiple Sclerosis International},
  year = {2011},
  doi = {10.1155/2011/271321}
}
Kostenlos starten →